A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure

Trial Profile

A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms POPLAR
  • Sponsors Roche
  • Most Recent Events

    • 21 Jul 2017 According to a Roche media release, The EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ (atezolizumab) as a monotherapy. People with EGFR activating mutations or ALK positive tumour mutations should also have received targeted therapy before receiving TECENTRIQ. This positive recommendation is based on results from the OAK study and the POPLAR study.
    • 06 Jun 2017 Results weighing and comparing cost and value of Nivolumab, Atezolizumab and Pembrolizumab vs. Docetaxel using patient data from KEYNOTE-010, POPLAR, Checkmate 057, Checkmate-017 and one other trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results assessing predictive performance of TUK metrics developed using data from POPLAR trial for the prediction of outcome of the atezolizumab in OAK trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top